{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:35:33Z","timestamp":1790368533250,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T00:00:00Z","timestamp":1360713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/2050-6511-14-12","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T09:14:39Z","timestamp":1360746879000},"source":"Crossref","is-referenced-by-count":47,"title":["Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study"],"prefix":"10.1186","volume":"14","author":[{"suffix":"II","given":"Ronald G","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A","family":"Hazlewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara D","family":"Brouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal K","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chistopher R","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Bedimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,13]]},"reference":[{"key":"116_CR1","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","volume":"166","author":"LK Hidayat","year":"2006","unstructured":"Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006, 166: 2138-2144. 10.1001\/archinte.166.19.2138.","journal-title":"Arch Intern Med"},{"key":"116_CR2","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Graves J, Evans A: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008, 52: 3315-3320. 10.1128\/AAC.00113-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"116_CR3","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","volume":"42","author":"G Sakoulas","year":"2004","unstructured":"Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004, 42: 2398-2402. 10.1128\/JCM.42.6.2398-2402.2004.","journal-title":"J Clin Microbiol"},{"key":"116_CR4","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1128\/JCM.01388-06","volume":"44","author":"G Wang","year":"2006","unstructured":"Wang G, Hindler JF, Ward KW, Bruckner DA: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006, 44: 3883-3886. 10.1128\/JCM.01388-06.","journal-title":"J Clin Microbiol"},{"key":"116_CR5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1086\/513203","volume":"44","author":"FC Tenover","year":"2007","unstructured":"Tenover FC, Moellering RC: The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for staphylococcus aureus. Clin Infect Dis. 2007, 44: 1208-1215. 10.1086\/513203.","journal-title":"Clin Infect Dis"},{"key":"116_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009, 66: 82-98. 10.2146\/ajhp080434.","journal-title":"Am J Health Syst Pharm"},{"key":"116_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH: A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007, 29: 1107-1115. 10.1016\/j.clinthera.2007.06.014.","journal-title":"Clin Ther"},{"key":"116_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009, 49: 507-514. 10.1086\/600884.","journal-title":"Clin Infect Dis"},{"key":"116_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.amjmed.2010.07.025","volume":"123","author":"L Pritchard","year":"2010","unstructured":"Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB: Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010, 123: 1143-1149. 10.1016\/j.amjmed.2010.07.025.","journal-title":"Am J Med"},{"key":"116_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","volume":"52","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, Rybak MJ: Impact of vancomycin exposure on outcomes in patients with methicillin-resistant staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011, 52: 975-981. 10.1093\/cid\/cir124.","journal-title":"Clin Infect Dis"},{"key":"116_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1471-2334-12-104","volume":"12","author":"RG Hall","year":"2012","unstructured":"Hall RG, Giuliano CA, Haase KK: Empiric guideline-recommended weight based dosing and mortality in methcillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect Dis. 2012, 12: 104-10.1186\/1471-2334-12-104.","journal-title":"BMC Infect Dis"},{"key":"116_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159\/000180580.","journal-title":"Nephron"},{"key":"116_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-383. 10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"116_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","volume":"115","author":"JW Chow","year":"1991","unstructured":"Chow JW, Fine MJ, Shlaes DM: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991, 115: 585-590.","journal-title":"Ann Intern Med"},{"key":"116_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","volume":"11","author":"JW Chow","year":"1999","unstructured":"Chow JW, Yu VL: Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999, 11: 7-12. 10.1016\/S0924-8579(98)00060-0.","journal-title":"Int J Antimicrob Agents"},{"key":"116_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3027-2","volume-title":"Recursive partitioning in the health sciences","author":"H Zhang","year":"1999","unstructured":"Zhang H, Singer B: Recursive partitioning in the health sciences. 1999, New York: Springer"},{"key":"116_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/SHK.0b013e318182f98f","volume":"31","author":"JY Rhee","year":"2009","unstructured":"Rhee JY, Kwon KT, Ki HK: Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2009, 31: 146-150. 10.1097\/SHK.0b013e318182f98f.","journal-title":"Shock"},{"key":"116_CR18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004, 38: 1673-1681. 10.1086\/420818.","journal-title":"Clin Infect Dis"},{"key":"116_CR19","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/431675","volume":"41","author":"EJ Ellis-Grosse","year":"2005","unstructured":"Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005, 41: S341-S353. 10.1086\/431675.","journal-title":"Clin Infect Dis"},{"key":"116_CR20","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","volume":"49","author":"J Weigelt","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005, 49: 2260-2266. 10.1128\/AAC.49.6.2260-2266.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"116_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/595686","volume":"48","author":"MH Wilcox","year":"2009","unstructured":"Wilcox MH, Tack KJ, Bouza E: Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009, 48: 203-212. 10.1086\/595686.","journal-title":"Clin Infect Dis"},{"key":"116_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1001\/archinte.1989.00390080053013","volume":"149","author":"NJ Downs","year":"1989","unstructured":"Downs NJ, Neihart RE, Dolezal JM, Hodges GR: Mild nephrotoxicity associated with vancomycin use. Arch Intern Med. 1989, 149: 1777-1781. 10.1001\/archinte.1989.00390080053013.","journal-title":"Arch Intern Med"},{"key":"116_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jac\/16.2.235","volume":"16","author":"TC Sorrell","year":"1985","unstructured":"Sorrell TC, Collignon PJ: A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother. 1985, 16: 235-241. 10.1093\/jac\/16.2.235.","journal-title":"J Antimicrob Chemother"},{"key":"116_CR24","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008, 52: 1330-1336. 10.1128\/AAC.01602-07.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2050-6511-14-12\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:24:27Z","timestamp":1581963867000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/2050-6511-14-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,13]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["116"],"URL":"https:\/\/doi.org\/10.1186\/2050-6511-14-12","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,13]]},"article-number":"12"}}